Recent Updates
Recently added Catalysts
VALN Positive Sentiment

Valneva Half-Year 2026 Financial Report

Thursday, August 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Valneva SE released its Half-Year 2026 Financial Report, highlighting strong financial performance. The report also noted that the marketing authorization application for its Lyme disease vaccine candidate, developed in collaboration with Pfizer, was validated by the European Medicines Agency. This application is based on positive results from the Phase 3 VALOR trial.
Price reaction · baseline $5.53 (2026-08-13T15:29:00.000Z) · hit during market hours · clean, no other VALN news in the window
day 0 close · peak
+2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Valneva's financial report shows strong performance indicators.
  • The marketing authorization application for the Lyme disease vaccine was validated.
  • The Phase 3 VALOR trial demonstrated favorable efficacy and safety results.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
3.7%
average across 6 past catalysts
Lead asset
VLA1553 full dose
Phase 2 · Chikungunya Virus Infection

Full Press Release Details

Attachment
• Financial Report HY1 2026 (EN) (2026-08-12) (002)

Recommended Reading

• September 04, 2026 12:00 ET | Source: VALNEVA SE Declaration of shares and voting rights - Status as of August 31, 2026 VALNEVA Declaration of shares and voting rights Status as of August 31, 2026__________________________________________________________________________________________ Company name:... Read More
• August 14, 2026 01:00 ET | Source: VALNEVA SE Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris:... Read More
VALNEVA Declaration of shares and voting rights Status as of August 31, 2026__________________________________________________________________________________________ Company name:...
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris:...

Frequently Asked Questions

What did Valneva's Half-Year 2026 report highlight?

The report highlighted strong financial performance and a validated Lyme disease vaccine application.

Who collaborated with Valneva on the Lyme vaccine?

Valneva collaborated with Pfizer on the Lyme disease vaccine candidate.

What trial results supported the vaccine application?

The application was based on favorable results from the Phase 3 VALOR trial.

Which agency validated Valneva's vaccine application?

The European Medicines Agency validated Valneva's marketing authorization application.

ShareAdd on Google
Tags: VALN Valneva Lyme disease vaccine Phase 3 VALOR trial financial report Pfizer
Last updated: Aug 13, 2026

Biotech snapshot

Lead asset
VLA1553 full dosePhase 2
Chikungunya Virus Infection →

Catalyst track record

+8%
best trade around VALN's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VALN.

See every catalyst's timing & PoA →